Tumor News and Research

RSS

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Remarkable properties of new, porous material could lead to advances in microscopic sponging

The sponges of the future will do more than clean house. Picture this, for example: Doctors use a tiny sponge to soak up a drug and deliver it directly to a tumor. Chemists at a manufacturing plant use another to trap and store unwanted gases.

28 Jan 2014

Researchers identify therapeutic target for cervix cancer

Gene related to the proliferation of cancerous cells blocked through molecular technology. A group of researchers from Mexico's General Hospital, Health Secretariat, Medicine Faculty and the Institute of Cellular Physiology of the National Autonomous University of Mexico (UNAM) identified a therapeutic target for cervix cancer: gene CDKN3.

28 Jan 2014

Response of brain tumors from SRS can indicate necessity of follow-up treatments

The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.

28 Jan 2014

New modular structures 'glued' with DNA to deliver cancer medications

A team of researchers at the University of Toronto has discovered a method of assembling "building blocks" of gold nanoparticles as the vehicle to deliver cancer medications or cancer-identifying markers directly into cancerous tumors.

28 Jan 2014

Researchers develop valid humanized model for facioscapulohumeral muscular dystrophy

Researchers at the Kennedy Krieger Institute recently announced study findings showing the successful development of a humanized preclinical model for facioscapulohumeral muscular dystrophy (FSHD), providing scientists with a much needed tool to accelerate novel therapeutic research and development.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

Practicing yoga for atleast 3 months can reduce fatigue and inflammation in breast cancer survivors

Practicing yoga for as little as three months can reduce fatigue and lower inflammation in breast cancer survivors, according to new research.

27 Jan 2014

South Korean lung SCC genetic secrets revealed

Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say.

27 Jan 2014

Study demonstrates direct effects of fragmented sleep on tumor growth

Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.

27 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.

27 Jan 2014

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

A landmark study across many cancer types reveals that the universe of cancer mutations is much bigger than previously thought. By analyzing the genomes of thousands of patients' tumors, a Broad Institute-led research team has discovered many new cancer genes - expanding the list of known genes tied to these cancers by 25 percent. Moreover, the study shows that many key cancer genes still remain to be discovered.

25 Jan 2014

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma.

25 Jan 2014

Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

25 Jan 2014

Scientists develop powerful RapidCaP mouse models for metastatic prostate cancer

Prostate cancer is the most common form of cancer in men. Affecting about 1 in 6 men, it is the second deadliest cancer. Research has been stymied by imperfect animal models of the disease, which are costly, take considerable time to develop, and fail to mimic the most lethal aspects of the illness.

25 Jan 2014

Novel HER2 mutation identified in familial lung adenocarcinomas

Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas.

24 Jan 2014

Scientists identify genetic alterations in pediatric soft-tissue cancer

Scientists have mapped the genetic changes that drive tumors in rhabdomyosarcoma, a pediatric soft-tissue cancer, and found that the disease is characterized by two distinct genotypes. The genetic alterations identified in this malignancy could be useful in developing targeted diagnostic tools and treatments for children with the disease. The study, by researchers at the National Cancer Institute, part of the National Institutes of Health, and their colleagues, appeared in the Jan. 23, 2014, issue of the journal Cancer Discovery.

24 Jan 2014

Aspirin intake correlates with halted growth of lethal intracranial tumor

Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

24 Jan 2014

Tumor News and Research

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Remarkable properties of new, porous material could lead to advances in microscopic sponging

Researchers identify therapeutic target for cervix cancer

Response of brain tumors from SRS can indicate necessity of follow-up treatments

New modular structures 'glued' with DNA to deliver cancer medications

Researchers develop valid humanized model for facioscapulohumeral muscular dystrophy

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Practicing yoga for atleast 3 months can reduce fatigue and inflammation in breast cancer survivors

South Korean lung SCC genetic secrets revealed

Study demonstrates direct effects of fragmented sleep on tumor growth

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

Scientists develop powerful RapidCaP mouse models for metastatic prostate cancer

Novel HER2 mutation identified in familial lung adenocarcinomas

Scientists identify genetic alterations in pediatric soft-tissue cancer

Aspirin intake correlates with halted growth of lethal intracranial tumor

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News